NCT03999710

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.

Conditions

• Non Small Cell Lung Cancer
• Lung Cancer
• Nsclc
• NSCLC Stage II
• NSCLC, Stage III

Interventions

Type	Name	Description
RADIATION	Radiation Therapy	Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
DRUG	Durvalumab	A dose of 1500mg (for patients \>30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.

Timeline

• Start date: 2019-07-19
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2019-06-27
• Last updated: 2025-11-28

Locations

9 sites across 1 country: United States

Regulatory

• FDA-regulated drug study